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SUPPLEMENTARY NOTES
ABSTRACT
The purpose of this project is to develop and test a system that identifies in real time the effects of breast cancer cells on gene transcription by cells in their microenvironment. The accomplishment of this goal will identify messages induced in normal cells adjacent to cancer cells that support cancer cell growth and survival. In this Concept award project, we are testing whether breast cancer cells that make lysyl oxidase (a metastasis promoting enzyme) or have lysyl oxidase suppressed differ in their ability to turn on hospitable genes in bone marrow stromal cells. We have successfully tagged bone marrow stromal cells with a protozoal enzyme (uracil phosphoribosyl transferase) that enables us to measure ongoing stromal cell transcription when stroma is mixed with breast cancer cells. Real time transcription specific to the stromal cell compartment was able to be measured without disaggregating stromal and cancer cells, so that genetic signals arising from cell cell contact between stroma and cancer cellscould be captured. A global assessment of stromal genes induced by high versus low metastatic cancer cells is planned. This project is likely to help guide the development of stromal-based therapeutics. The initial focus is on interactions between tumor cells and bone marrow stroma. No studies to date have examined the effects of breast cancer cells on global gene transcription in bone marrow stroma. It has recently been shown that even a static genetic signature in the stroma of primary breast cancer tumors is prognostic of cancer outcome (4) . An underling hypothesis of this proposal is that that breast cancer bone metastasis depends upon gene expression cascades that are reinforced by both juxtacrine (cell-cell contact) and paracrine loops between bone marrow stroma and tumor cells. It is also hypothesized that these gene expression cascades depend on the expression of lysyl oxidase that has been shown to be required for sustaining metastasis in a murine model (1).
SUBJECT TERMS
Our approach to testing this hypothesis has been to transduce human HS-27a bone marrow stromal cells (5) with the toxoplasma gondii enzyme uracil phosphoribosyl transferase (UPRT) constructed as a fusion protein with a C-terminal fluorescent tag (yellow fluorescent protein (YFP)). This enzyme enables eukaryotic cells to incorporate exogenous thiouracil into their RNA (3). RNAs synthesized during a thiouracil pulse are subsequently labeled with biotin and isolated on streptavidin beads. RNA that is concurrently harvested from cocultured breast cancer cells lacks thiol-tags and is therefore not biotinylated or isolated on the beads. Microarray analysis of bead-purified mRNA from mixtures of stromal and cancer cells will therefore specifically detect the stromal cell transcripts that were made during the thiouracil pulse. In order to determine the effects of cancer cell lysyl oxidase on transcription in adacent bone marrow stromal cells, the stromal cells have been cocultured either with MDA-MB-231 cells expressing vector control or LOX knockdown shRNA. These cancer cells are tagged with red fluorescent protein (dsRed2) in order easily to visualize the mixing of the cancer cells on the stromal monolayer. Controls include stromal cells and cancer cells cultured alone. In order to distinguish juxtacrine versus paracrine interactions, another control consists of stromal cells exposed to conditioned medium from the cancer cells. Figure The goal of this strategy is to identify novel components of a cancer-stroma communication network that are amenable to targeted therapy.
BODY
The following steps are important components of our project execution, as listed in our Statement of Work. We have made significant progress in this project, completing SOW goals #1, 3, 4, 5, 6, 7 and 8. SOW #2 focused on an alternative stromal cell line to use in this work but multiple cultures were nonviable and this alternative was dropped. Work was delayed because of difficulty in generating red fluorescent breast cancer cells in which lysyl oxidase expression was stably suppressed. Initial attempts to do this using interfering RNA were not successful. We have now succeeded in this aim (SOW #4) that is a key component of completing the work. The modified lysyl oxidase knockdown and control cells were then able to be used in mixing experiments with stromal cells (SOW 8) this past month.
Sections below summarize or report our data relative to the SOW.
SOW 1)
Establish bone marrow stromal cell lines stably transfected with a YFP-UPRT (uracil phosphoribosyltransferase) fusion protein.
We have successfully transduced and stably expressed a YFP-UPRT transgene in the the HS-27a stromal cell line (5) (Figure 2 ) 
SOW 7)
Optimize isolation of thiouracil pulsed mRNA. After extensive testing, we have found that MPG streptavidin beads and M-280 streptavidin dynabeads are optimal for thiolated-biotinylated mRNA isolation. We have optimized bead to biotinylated mRNA at 1 ul (5 mg/ml) beads per 5 ug of UPRT mRNA, reaction volume at 4X the bead volume and wash volume at 12X the bead volume; protocol is otherwise as in reference 3. SOW 9) Biotinylate thiouracil-pulsed mRNA and isolate it on streptavidin beads. See Figure 5 above. Figure 6 Northern blot (above) shows presence of eluted GAPDH + Actin detectable in elutants from HS27a stromal cells incubated with 4-thiouracil (4-TU) but not with DMSO vehicle. A range of exposures showed lack of message in DMSO elutants and presence in 4-TU elutants (not shown). Streptavidin western blotting showed that only the cells exposed to 4-TU could be biotinylated and that ~90% of the biotinylated mRNA was captured by the beads and absent in the flowthrough. SOW 10) Use isolated biotinylated mRNA to probe expression microarrays. We are scaling up in order to do this during a no-cost extension year SOW 11) Analyze results. We will conduct bioinformatic analyses and validation during a no-cost extension year.
KEY RESEARCH ACCOMPLISHMENTS
•Specific thiol-labeling of stromal cell mRNA within a heterogeneous cell mixture can be achieved using a YFP-UPRT transgene.
•Stable downmodulation of lysyl oxidase mRNA in MDA-MB-231 breast cancer cells.
•Demonstration of functionality of a YFP-UPRT transgene.
•Tagged stromal cell mRNA can be efficiently recovered from a mixture of RNAs from different cell types. The technique used in this proposal features unprecedented real-time dynamic characterization of bone marrow stromal cell-specific transcription without disrupting cell-cell contacts. Despite theimportance of cancer cell-stromal interactions, current approaches are poorly suited toanalyze the effect of cancer cells on their microenvironment (and vice versa) within intact tumors. By laying the groundwork for such in vivo analysis, these investigations should make it feasible for the first time to kinetically profile transcription that arises from cell-cell contacts in distinct subsets of cells within tumors.
REPORTABLE OUTCOMES
The ability to specifically label stromal cell mRNA during a pulse could be adapted to examine stromal cell transcription in different time windows after contact with breast cancer cells, or in the context cancer cell or stromal cell exposure to drugs. Lastly, we have prepared all necessary reagents to test whether lysyl oxidase sup[ports metastatic aggressiveness of breast cancer cells by enabling them to durably alter the transcription in neighboring bone marrow stromal cells in ways that less aggressive breast cancer cells do not.
